Literature DB >> 21577142

Differential expression and function of α-mannosidase I in stimulated naive and memory CD4+ T cells.

Inga Gebuhr1, Kathrin Keeren, Katrin Vogt, Conny Höflich, Christine Appelt, Ulrike Schlieer, Christine Brandt, Christian Meisel, Hans-Dieter Volk, Birgit Sawitzki.   

Abstract

N-linked protein glycosylation represents an important cellular process for modifying protein properties. It resembles a cascade of various enzymatic reactions, in which class I α-mannosidases play a central role. We and others have recently shown that N-glycosylation plays a major role for immune functions. We now analyzed the expression and function of α-mannosidase I in CD4(+) naive and memory T cells studying human and murine T cells. Alpha-mannosidase I function was altered by (i) treatment with Kifunensine, a specific inhibitor class I α-mannosidases, (ii) synthetic inhibitory RNA, and (iii) overexpression by retroviral gene transfer. T-cell activation was evaluated by CD69 expression, cytokine production and proliferation. Our results demonstrate (i) that α-mannosidase I transcription is transiently downregulated after T-cell activation with either polyclonal anti-CD3/CD28 antibodies or allogeneic CD19(+) B cells, and (ii) that α-mannosidase I exerts an inhibitory effect on T-cell activation. It is interesting to note that the inhibitory effect was restricted to naive CD4(+) T cells in both systems, human T cells and murine transgenic CD4(+)OT-II cells, whereas human memory T cells and primed CD4(+)OT-II cells remained unaffected. Alpha-mannosidase I inhibition reduced the activation threshold for naive but not already primed CD4(+)OT-II cells as the cells were able to respond to lower ovalbumin peptide concentrations and increased the rejection potential of alloreactive T cells in vivo. Thus, complex N-glycans generated by enzymes such as α-mannosidase I inhibit the activation of naive T cells. These findings could be used to improve the ex vivo priming of naive T cells for adaptive T-cell therapies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21577142     DOI: 10.1097/CJI.0b013e31821dcf23

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  5 in total

1.  Impact of the gut microbiota on enhancer accessibility in gut intraepithelial lymphocytes.

Authors:  Nicholas P Semenkovich; Joseph D Planer; Philip P Ahern; Nicholas W Griffin; Charles Y Lin; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-01       Impact factor: 11.205

2.  Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood Toll-like receptor 5 mRNA expression.

Authors:  Birgit Sawitzki; Claudio Brunstein; Christian Meisel; Julia Schumann; Katrin Vogt; Christine Appelt; Julie M Curtsinger; Michael R Verneris; Jeffrey S Miller; John E Wagner; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-01       Impact factor: 5.742

3.  Gene signatures associated with adaptive humoral immunity following seasonal influenza A/H1N1 vaccination.

Authors:  I G Ovsyannikova; H M Salk; R B Kennedy; I H Haralambieva; M T Zimmermann; D E Grill; A L Oberg; G A Poland
Journal:  Genes Immun       Date:  2016-08-18       Impact factor: 2.676

4.  An Exploration of Gene-Gene Interactions and Their Effects on Hypertension.

Authors:  Ying Meng; Susan Groth; Jill R Quinn; John Bisognano; Tong Tong Wu
Journal:  Int J Genomics       Date:  2017-05-31       Impact factor: 2.326

5.  Effect of induction therapy on the expression of molecular markers associated with rejection and tolerance.

Authors:  Eva Krepsova; Irena Tycova; Alena Sekerkova; Peter Wohlfahrt; Petra Hruba; Ilja Striz; Birgit Sawitzki; Ondrej Viklicky
Journal:  BMC Nephrol       Date:  2015-08-19       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.